Veno-occlusive disease (VOD) is a serious complication of myeloablative therapy and stem cell transplantation. We here describe a case of VOD in a patient with acute myeloid leukemia (AML), who received an autologous peripheral blood stem cell graft after busulphan/ cyclophosphamide conditioning in first complete remission and who developed severe VOD at day 17. Color-flow sonography of the portal and hepatic veins revealed hepatofugal blood flow in the portal vein and an absence of flow in the hepatic vein. Treatment with recombinant tissue plasminogen activator (t-PA) was started at a dose of 10 mg/day and increased to 20 mg/day because color-flow sonography indicated no change of blood flow. Daily sonography was continued to monitor the portal and hepatic blood flow in order to assess the need for continuation of t-PA. Once an objective sonographic improvement was observed, t-PA treatment was tapered and stopped. This case demonstrates that color-flow sonography can be used to confirm the clinical diagnosis of VOD. Furthermore this technique provides a way for easily and reliably evaluating the effect in relation to dose of thrombolytic therapy needed. It improves the quality of clinical monitoring which is needed for effective treatment of VOD while minimizing the risk of serious bleeding complications. Keywords: stem cell transplantation; tPA; VOD; venoocclusive disease; echography
symptoms around day 20 after the high-dose cytotoxic regimen which precedes stem cell reinfusion. The incidence of VOD is reported to vary from 1 to 54% and is higher in patients with adverse prognostic factors such as high risk malignant disease, a conditioning regimen including busulphan and immunogenetic compatibility between donor and transplant recipient. [1] [2] [3] [4] [5] The outcome of VOD is fatal in up to 53% of patients, in spite of various therapeutic measures such as heparin administration. 2, [5] [6] [7] [8] [9] [10] At present the optimal treatment of VOD has not yet been defined, although recently some promising results have been reported following the use of recombinant tissue plasminogen activator (t-PA). [11] [12] [13] [14] [15] [16] For effective treatment it is important to diagnose VOD at an early stage so that thrombolytic therapy can be initiated before serious organ failure has developed. In addition, in order to avoid serious bleeding complications careful monitoring of the therapeutic effect is warranted. In this report, we describe a patient with acute myeloid leukemia who developed VOD after autologous peripheral blood stem cell transplantation. Color-flow imaging sonography was performed to confirm the clinical diagnosis of VOD and repeated daily to monitor the portal end hepatic blood flow during thrombolytic therapy with t-PA.
Patient and methods
The patient is a previously healthy male, who was admitted at the age of 17 with acute myeloid leukemia, FAB classification M1, with 95% blasts in the bone marrow smear. The peripheral blood count showed leukocytosis (50.8 ϫ 10 9 /l), anemia (hemoglobin, 5.4 mmol/l) and thrombocytopenia (16 ϫ 10 9 /l). At diagnosis, the liver indices including bilirubin, serum ␥-glutamyl transferase, serum alkaline phosphatase, serum alanine aminotransferase (ALAT) and serum aspartate aminotransferase (ASAT) were normal. /kg CD34-positive cells. During the hypoplastic phase after the first induction cycle, the patient had a febrile episode related to inflammation of the maxillary sinus for which he was treated with antibiotics including vancomycin and amphotericin B. Fever resolved and no further complications occurred. Based on morphological examination of the bone marrow aspirate and peripheral blood smear the patient attained a partial remission after induction cycle 1 (6% bone marrow blasts) and a complete remission after cycle 2.
Ten days later the patient was readmitted to the hospital for intensification therapy, which included a preparative regimen consisting of busulphan 4 mg/kg/day for 4 days and cyclophosphamide 60 mg/kg/day for 2 days, followed by the reinfusion of the stem cell autograft. The initial postinfusion period was uncomplicated except for a 3-day episode of fever of unknown origin (FUO) for which he was treated with intravenous antibiotics. At that time no deviations of the liver enzymes had occurred.
Results
On day 17 after transplantation, the patient acutely developed progressive hyperbilirubinemia, hepatomegaly, tenderness of the upper abdomen and clinical symptoms of ascites. The total serum bilirubin rose from 0.4 to 2.7 mg/dl and the serum creatinin rose from 0.5 to 1.7 mg/dl within 24 h. Diuresis declined to 0.5 l per 24 h. In addition, the patient gained weight of 10 kg within 3 days (14% increment of body weight) and generalized edema developed.
Sonography of the abdomen revealed the presence of ascites and hepatomegaly with a largest hepatic diameter of 24 cm. In addition, color-flow imaging and duplex sonography using a Toshiba 270 (Tokyo, Japan) and an Aloka 2000 (ATL, Bothell, WA, USA) ultrasound machine showed that the blood flow in the portal vein had reversed from hepatopetal to hepatofugal with a net negative blood flow of approximately Ϫ10 cm/s (Figure 1 ). The pulsative pattern indicated arterio-portal shunting. No blood flow in the hepatic vein could be detected. Hepatic artery flow was not quantified in this patient. Coagulation tests and viral serology tests failed to show evidence of consumptive coagulopathy or active hepatitis. The clinical symptoms and abnormal findings on sonography were interpreted as early evidence of veno-occlusive disease (VOD). Because of the rapid onset of hyperbilirubinemia, the rapid development of significant edema, ascites and weight gain, VOD in this patient was regarded as life-threatening although not strictly classified as severe.
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Within 24 h after the clinical onset of VOD, thrombolytic therapy with recombinant t-PA (Actilyse; Boehringer, Ingelheim, Germany), was started at a loading dose of 10 mg administered through a central venous catheter, followed by a 4-h infusion of 10 mg on 2 consecutive days. Thrombolytic treatment was combined with heparin (Novo Industries, Denmark), 5000 U intravenous bolus followed by a continuous infusion at a rate of 200 U/kg/day. Because of the coexisting von Willebrands disease in this patient, Factor VIII concentrate (Hemate P; Hoechst, Roussel, The Netherlands) was administered at a rate of 20 U/kg/day for 5 days.
In order to monitor the effect of t-PA administration, daily color sonography of the portal and the hepatic veins was performed. At 48 h after the start of t-PA the portal and hepatic vein blood flow had not improved. Therefore, the daily dose of t-PA was subsequently increased to 20 mg/day. At 24 h after the dose of t-PA had been doubled, color sonography showed a reversal of the blood flow in the portal vein, resulting in a restoration of the hepatopetal flow to a value of 24.9 cm/s and that of the hepatic vein flow to 51.9 cm/s (Figure 2) . However, the flow pattern remained pulsative, and at that time also collateral flow through the Ligamentum falciformis was still observed. Therefore, treatment with t-PA was continued at the same dose for an additional 3 days with continuation of the daily monitoring of the hepatic and portal vein flow. At day 7, all signs of collateral circulation through the Ligamentum falciformis had disappeared, and the portal and hepatic vein flow normalized. Concomitantly, the condition of the patient rapidly improved. Heparin was discontinued 4 days after discontinuation of t-PA. At day 10 after the onset of VOD, the total serum bilirubin was 0.4 mg/dl (normal) and there were no residual signs of ascites or liver enlargement by sonography. The body weight had returned to normal. There were no signs of impaired blood flow in the portal and hepatic veins apparent by sonography. At 6 months after the onset of VOD the patient is healthy and without any sign of liver function impairment.
Discussion
VOD is a serious complication of bone marrow transplantation which occurs in 4-54% of patients. [2] [3] [4] [5] 7, 17 In patients treated with autologous stem cell transplantation it is rarer (4-11%), but the clinical course is similar. [2] [3] [4] [5] 7, 8, 17, 18 Risk factors for VOD that may apply to autologous transplants include pre-existing liver disease, prior treatment for infectious diseases with antibiotics and amphotericin B. Conditioning regimens which include busulphan may be associated with an increased risk of VOD. 1 The mortality rate varies among different studies but appears to correlate with the severity of symptoms, ie, the development of multiorgan failure, the requirement for hemodialysis and severe liver dysfunction. 1 The early recognition of VOD and timely initiation of effective antithrombotic therapy are essential elements of the clinical treatment of VOD. At present the cornerstone of VOD treatment is tPA combined with heparin. 1, 11, 13, 14 Although administration of tPA may lead to an improved outcome of VOD, the results in patients who have developed multiorgan failure are unfavorable. A prospective study that was performed to evaluate the role of conventional ultrasound detection of VOD, showed that this technique is not sensitive enough to diagnose patients with early VOD. 19 Doppler ultrasound however, may demonstrate reduced portal vein flow in patients with VOD. 20 In the present patient, we were able to demonstrate that color-flow imaging is a sensitive and reproducible technique to detect hepatofugal blood flow in the portal vein at an early clinical stage of VOD. The pulsative pattern in the portal vein is caused by shunting between the hepatic artery and the portal vein. This can be observed in venous outflow problems of the liver and can occur at each level, ie hepatic vein, small venules or the sinusoid. 21 With the same technique, the flow in the hepatic vein was found to be reduced. In combination with the presence of ascites, these findings provided definite evidence that VOD was present in our patient. It should be remembered however, that VOD without flow abnormalities has been described repeatedly. Most likely, the sensitivity and specificity of the ultrasound technique used is of great importance to determine the pathophysiologic events in this disease. In our patient this technique appeared to be a succesful and convenient way to monitor the effect of antithrombotic therapy. By using color-flow imaging it was possible to determine the dose of tPA which was needed for thrombolysis and to avoid the bleeding complications associated with overdosing with tPA. Based on this monitoring approach it was concluded at 48 h after start of tPA that the flow in the portal vein had not improved, a finding that contributed to the decision to escalate the dose of tPA. Since tPA administration is associated with a significant risk of bleeding complications, we wished to limit the dose and duration of tPA administration to the minimum. Daily monitoring during tPA therapy permitted us to determine the moment of tPA discontinuation exactly. This is of specific interest in patients who have received myeloablative treatment and who are subject to mucosal bleeding and prolonged thrombocytopenia.
In conclusion, Doppler, color-flow imaging may be used for day-to-day monitoring of patients with VOD, who have flow abnormalities in the portal vein. Its repeated use makes it possible to determine more accurately the need to initiate or to stop thrombolytic therapy. Its routine use should be considered in all patients who are suspected of VOD.
